Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial ...

Maintaining remission in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who have kept their autoantibodies in check after at least 2 years on rituximab therapy has ...

This report delivers an in-depth understanding of the ANCA Associated Vasculitis, historical and forecasted epidemiology as well as the ANCA Associated Vasculitis market trends in the United ...

Likewise, a positive result may not necessarily be sufficient to diagnose an ANCA-associated vasculitis. MPA is the most common type of ANCA-associated small vessel vasculitis. It is more ...

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a systemic small-vessel vasculitis comprising three clinical syndromes: granulomatosis with polyangiitis (formerly known as ...

The reemergence of myeloperoxidase-antineutrophil cytoplasmic antibodies — or MPO-ANCA — can serve as a biomarker to predict relapse in patients who achieved remission in MPO-ANCA–positive ...

This global study of 331 patients with ANCA vasculitis met both of its primary endpoints, disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham ...

ANCA testing is more commonly used to diagnose vasculitis, a group of autoimmune disorders that affect small blood vessels. In vasculitis, ANCAs attach to neutrophils and cause them to attack the ...

If you have lupus associated with ANCA your risk for vasculitis is higher. ANCA vasculitis can affect blood vessels in your kidneys and other organs. It’s not common, but your doctor can run a ...

The formation of neutrophil extracellular traps (NETs) is a common feature in the renal glomeruli of patients with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. The use of a DNA repair ...